Company Overview of Adheron Therapeutics, Inc.
Adheron Therapeutics, Inc. develops pharmaceuticals for the treatment of rheumatoid arthritis and fibrotic diseases. Its product SDP051, is a Cad-11 antagonist that acts as an adhesive between cells and changes in these Cad-11 interactions can induce the cells to produce many proteins that influence the cellular environment positively or adversely. The company's product is used in pulmonary fibrosis and skin fibrosis. Adheron Therapeutics, Inc. was formerly known as Synovex Corporation. The company was incorporated in 2003 and is based in Berkeley, California. As of October, 2015, Adheron Therapeutics, Inc. operates as a subsidiary of Roche Holding AG.
2930 Domingo Avenue
Mail Boxes Plus
Mail Box 104
Berkeley, CA 94705
Founded in 2003
Key Executives for Adheron Therapeutics, Inc.
Similar Private Companies By Industry
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|4P Therapeutics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
|7 Oaks Pharmaceutical Corp.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
To contact Adheron Therapeutics, Inc., please visit adherontherapeutics.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.